Castomize's heat-molded 3D-printed orthopedic cast reduces costs by up to 25%

Singapore-based startup Castomize has commercialized a heat-molded 3D-printed orthopedic cast for wrist, arm, and ankle fractures that is breathable, lightweight, and fully waterproof. The device, originating from a 2017 student project at Singapore University of Technology and Design, received medical clearance in Singapore last year and has since gained approval in Australia, South Korea, and Taiwan. Co-founder and CEO Abel Teo reports that in a Singapore hospital trial, the cast delivered average cost savings of 25% compared to traditional fiberglass casts, despite a 30-50% higher per-unit production cost. The company is now pursuing FDA approval in the US and CE marking in Europe, and is developing a sanitization process to enable reuse across multiple patients.

This development updates the recurring pattern of AM-enabled personalized medicine, specifically in the orthopedic and fracture-management segment. Unlike most custom-fit solutions that rely on 3D scanning for each patient, Castomize produces standard sizes and uses post-print heat molding to conform the cast to the individual limb. This approach reduces production time and cost, addressing a key barrier to adoption in cost-sensitive healthcare settings. The device competes with traditional fiberglass and plaster casts, as well as other 3D-printed custom orthoses from companies like ActivArmor and Xkelet. The cost savings from reduced recasting requirements—clinicians can reheat and reapply the same cast if fit issues arise—represent a meaningful operational efficiency for hospitals and clinics, particularly in volume-driven fracture care.

From an expert standpoint, Castomize's model is pragmatic: it avoids the per-patient scanning and design overhead that limits scalability for many custom medical AM applications. The key execution risk is regulatory—securing FDA 510(k) clearance and CE marking will determine whether this approach can scale beyond the Asia-Pacific markets where it is already cleared. The reuse sanitization process, if validated, could further improve the unit economics and make the cast competitive with conventional options on a per-use basis. For now, the company has demonstrated a viable path to cost-effective, mass-customizable fracture care that does not require a full digital workflow for every patient.